Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.
about
Pharmacological interventions for pruritus in adult palliative care patientsSyntheses of novel high affinity ligands for opioid receptorsEmerging therapies for patients with symptoms of opioid-induced bowel dysfunctionTreatment of opioid-induced gut dysfunctionVgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Peripherally acting mu-opioid receptor agonist attenuates neuropathic pain in rats after L5 spinal nerve injuryManaging opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.Review article: palliative care in gynecologic oncology.Neural correlates of an injury-free model of central sensitization induced by opioid withdrawal in humans.Opioid receptors in the gastrointestinal tract.Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects.Effects of methylnaltrexone on guinea pig gastrointestinal motility.New approaches to the treatment of opioid-induced constipation.Can the intestinal dysmotility of critical illness be differentiated from postoperative ileus?Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.Methylnaltrexone for the treatment of opioid-induced constipation.Natural product and natural product derived drugs in clinical trials.Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat modelThe Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients.Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region.Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
P2860
Q24241586-58222AA6-279D-4FA6-8009-A6AE2FE345F4Q24643984-6C0DDB60-08CD-4B7E-920C-6EE67DCC6016Q27010907-910A622A-842C-4B95-9352-A8AC49ADFE2AQ28284578-49533027-B305-407C-BE8B-9333250A8F01Q33296232-48859382-F75C-45BC-AE2A-77BAF624B25AQ33585535-BFB9022D-5865-4087-8C93-2922C3F17BEAQ33715430-E9619D13-E9E6-4E86-8DDD-131B04209D7DQ33973870-0844EE08-EB84-4AC2-9077-B73989766F33Q34156710-09B0AB82-73DB-4BC8-8FED-6B06394CA690Q34982888-0D7DF887-0F45-4E48-A45A-892AD77CCBB2Q35185222-84C37A5D-736C-444D-9862-ACE2939D3BD7Q36823204-081DAD40-2570-476D-9E93-EE2D3A4F9922Q36854395-C6B8E1C2-7796-46D4-9005-7D45DF45ECBEQ37299608-585C0B6F-75AC-4C67-8DBE-2B427829F22EQ37882496-1D567351-531A-449F-B056-657D316A0B63Q37993108-94D5973A-D278-417A-9D7F-C23F0973E32CQ38069607-2A681FBD-46AB-4E17-8B31-F97CB63C855AQ38247457-30382C28-73AA-4A5B-9CCA-8F95B0A1716AQ42014740-8A76958B-AE90-40D5-809A-4CCEED09A568Q43330788-A9D82BC4-69D7-4612-A343-8A4CEC1B452EQ44350809-D96F7342-4FA0-44BD-9D45-A15985EAF029Q52578077-C1ECC95C-D8FE-4CEC-ACF0-DE6D745FACB5
P2860
Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@ast
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@en
type
label
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@ast
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@en
prefLabel
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@ast
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@en
P2860
P1476
Methylnaltrexone, a novel peri ...... atment of opioid side effects.
@en
P2093
Chun-Su Yuan
Robert J Israel
P2860
P304
P356
10.1517/13543784.15.5.541
P407
P577
2006-05-01T00:00:00Z